Women with PMOS should get subsidised weight-loss drugs, Australian advocates say

With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label

• Get our breaking news email, free app or daily news podcast

Women living with a chronic hormonal condition should have access to taxpayer-funded weight-loss medications, advocates say.

The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.